Louis Weiner

..We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy...

..These immunomodulatory properties can form the basis for new cancer treatment strategies...

..Obstacles in developing effective cancer vaccines, including antigen selection, immunoediting, and tumor-mediated immunosuppression, are also discussed...

....

..Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer...

..This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway...

....

..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...

....

..Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of administration, toxicity concerns and insufficiently selective tumor targeting...

....

..Because high affinity may impair in vivo tumor targeting, a careful examination of Ab structure to function relationships is required to develop optimized therapeutic unconjugated Abs...

..These advances will be complemented by the use of antibodies that induce clinically meaningful host-protective immune responses. But, can we afford this progress?..

..Antibody conjugates have been used to deliver toxic principles, such as radioactive particles, chemotherapeutic agents, and catalytic toxins, with increasing success in clinical trials...

..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...

..Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib...

..This method provides an alternative approach to potentiate the therapeutic benefit of antitumor Abs that mediate ADCC...

..These manipulations hold the key to promoting tumor exposure and to ultimately creating successful Ab therapies for solid tumors...

....

..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...

..Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors...

..CONCLUSION: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer...

..To assess the benefits of aggressive chemoradiation therapy followed by surgery in resectable esophageal carcinoma...

....

..Both minibody constructs are stable in mouse and human serum for up to 72 h at 37 degrees C. These minibodies have the potential to target solid tumors and promote tumor lysis by natural killer cells and mononuclear phagocytes...

....

..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...

..The presence of skin rash and EGFR gene amplification have been advanced as possible predictors of clinical effectiveness of targeted anti-EGFR therapies...

..In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues...

..These scFvs provide a valuable and potentially clinically relevant panel of agents to target the members of the EGFR family...

..The incorporation of taxanes into induction strategies for esophageal cancer seems promising, but the optimal schedule remains undefined...

..25 %ID/g). These findings substantiate that the improved tumor retention of (sFv')2 homodimers over sFv monomers results from the availability of dual binding sites rather than from the slower systemic clearance of homodimers...

..Specific genes that regulate each of these mechanisms will be identified and exploited to improve antibody therapy. ..

..5 IgG1. These studies will identify candidate molecules for clinical development, and will provide a foundation for the clinically effective radioimmunotherapy of solid tumors. ..

..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..

..The successful execution of these studies will identify candidate strategies for the clinical exploitation of tumor-selective NK cell activation. ..

..The successful execution of these studies will identify candidate strategies for the clinical exploitation of tumor-selective NK cell activation. ..

..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..

..The successful achievement of these aims will identify new therapeutic reagents and strategies. ..

..Such information will provide future directions for the targeted cellular therapy of cancer...

....

..A candidate antibody for clinical development will emerge, as will generally useful information regarding the structural features of antibodies that contribute to ADCC and in vivo efficacy. ..